Access the full text.
Sign up today, get DeepDyve free for 14 days.
WR Miller
Form 90: A Structured Assessment Interview for Drinking and Related Behaviors.
A. Beyer, T. Koch, H. Schröder, S. Schulz, V. Höllt (2004)
Effect of the A118G polymorphism on binding affinity, potency and agonist‐mediated endocytosis, desensitization, and resensitization of the human mu‐opioid receptorJournal of Neurochemistry, 89
N. O'mara, L. Wesley (1994)
Naltrexone in the treatment of alcohol dependence.The Annals of pharmacotherapy, 28 2
W. Miller, J. Tonigan, R. Longabaugh, M. Mattson (1995)
The Drinker Inventory of Consequences (DrInC)
R. Anton, D. Moak, L. Waid, P. Latham, R. Malcolm, J. Dias (1999)
Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.The American journal of psychiatry, 156 11
C Gianoulakis, B Krishnan, J Thavundayil (1996)
Enhanced sensitivity of pituitary β-endorphin to ethanol in subjects at high risk of alcoholism [published correction appears in Arch Gen Psychiatry.1996;53(6):555]., 53
R. Anton, D. Moak, P. Latham (1996)
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies.Archives of general psychiatry, 53 3
(2004)
Medical Management (MM) Treatment Manual
M. Olive, Heather Koenig, M. Nannini, C. Hodge (2001)
Stimulation of Endorphin Neurotransmission in the Nucleus Accumbens by Ethanol, Cocaine, and AmphetamineThe Journal of Neuroscience, 21
R. Swift, H. Pettinati (2005)
Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence.Journal of studies on alcohol. Supplement, 15
J. Gelernter, H. Kranzler, J. Cubells (1999)
Genetics of two μ opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjectsMolecular Psychiatry, 4
MB First, RL Spitzer, M Gibbon, JBW Williams
Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition (SCID-I/P). Version 2.0.
(2004)
Combined Behavioral Intervention Manual
RF Anton, DH Moak, PK Latham (1996)
The Obsessive Compulsive Drinking Scale (OCDS): a new method of assessing outcome in alcoholism treatment studies [Arch Gen Psychiatry. 1996;53(7):576]., 53
N. Azrin, R. Sisson, R. Meyers, M. Godley (1982)
Alcoholism treatment by disulfiram and community reinforcement therapy.Journal of behavior therapy and experimental psychiatry, 13 2
W. Miller (1996)
Form 90: A Structured Assessment Interview for Drinking and Related Behaviors: Test Manual
WK Schmidt, SW Tam, GS Shotzberger, DH Smith, R Clark, VG Bernier (1985)
Nalbuphine., 14
J. Gelernter, R. Gueorguieva, H. Kranzler, Huiping Zhang, J. Cramer, R. Rosenheck, J. Krystal (2007)
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.Alcoholism, clinical and experimental research, 31 4
WR Miller, A Zweben, C DiClimente, R Rychtarik
Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence.
B. Johnson, N. Ait-Daoud, J. Roache (2005)
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.Journal of studies on alcohol. Supplement, 15
R. Longabaugh, A. Zweben, J. Locastro, W. Miller (2005)
Origins, issues and options in the development of the combined behavioral intervention.Journal of studies on alcohol. Supplement, 15
(1992)
Timeline followback: a technique for assessing selfreported ethanol consumption
S. O'Malley, A. Jaffe, S. Rode, B. Rounsaville (1996)
Experience of a "slip" among alcoholics treated with naltrexone or placebo.The American journal of psychiatry, 153 2
B. Mason (2005)
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.Journal of studies on alcohol. Supplement, 15
L. Ray, K. Hutchison (2004)
A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.Alcoholism, clinical and experimental research, 28 12
H. Pettinati, R. Weiss, W. Dundon, W. Miller, D. Donovan, Denise Ernst, B. Rounsaville (2005)
A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence.Journal of studies on alcohol. Supplement, 15
C. Barr, M. Schwandt, S. Lindell, Scott Chen, D. Goldman, S. Suomi, J. Higley, M. Heilig (2007)
Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques.Archives of general psychiatry, 64 3
(1995)
Twelve-Step Facilitation Therapy Manual: A Clinical Research Guide for
C. Streeton, G. Whelan (2001)
Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials.Alcohol and alcoholism, 36 6
J. Roberts, R. Anton, P. Latham, D. Moak (1999)
Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale.Alcoholism, clinical and experimental research, 23 9
J. Levine, N. Schooler (1986)
SAFTEE: a technique for the systematic assessment of side effects in clinical trials.Psychopharmacology bulletin, 22 2
R. Spitzer, M. First, M. Gibbon (1997)
Structured Clinical Interview for DSM-IV Axis I Disorders
J Nowinski, S Baker, K Carroll
Twelve-Step Facilitation Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence.
M. Hertzman (1996)
Clinical guide to alcohol treatment: The Community reinforcement approachJournal of Substance Abuse Treatment, 13
D. Oslin, W. Berrettini, H. Kranzler, H. Pettinati, J. Gelernter, J. Volpicelli, C. O'brien (2003)
A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent PatientsNeuropsychopharmacology, 28
Sung-Gon Kim, Cheol-Min Kim, D. Kang, Y. Kim, W. Byun, Seong-Yeon Kim, J. Park, Myung-Jung Kim, D. Oslin (2004)
Association of functional opioid receptor genotypes with alcohol dependence in Koreans.Alcoholism, clinical and experimental research, 28 7
R. Anton, C. Dominick, M. Bigelow, C. Westby (2001)
Comparison of Bio-Rad %CDT TIA and CDTect as laboratory markers of heavy alcohol use and their relationships with gamma-glutamyltransferase.Clinical chemistry, 47 10
WR Miller, JS Tonigan, R Longabaugh
The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse (Test Manual).
R. Anton, C. Lieber, B. Tabakoff (2002)
Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study.Alcoholism, clinical and experimental research, 26 8
C. Gianoulakis, Brinda Krishnan, J. Thavundayil (1996)
Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism.Archives of general psychiatry, 53 3
P. Marinelli, Li Bai, R. Quirion, C. Gianoulakis (2005)
A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration.Alcoholism, clinical and experimental research, 29 10
Ying Zhang, Danxin Wang, Andrew Johnson, A. Papp, W. Sadee (2005)
Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G*Journal of Biological Chemistry, 280
J. Zubieta, R. Dannals, J. Frost (1999)
Gender and age influences on human brain mu-opioid receptor binding measured by PET.The American journal of psychiatry, 156 6
J. Krystal, J. Cramer, W. Krol, G. Kirk, R. Rosenheck (2001)
Naltrexone in the treatment of alcohol dependence.The New England journal of medicine, 345 24
B. Mason, A. Goodman, S. Chabac, P. Lehert (2006)
Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.Journal of psychiatric research, 40 5
D. Gastfriend (2003)
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.Alcoholism, clinical and experimental research, 27 7
Badreddine Bencherif, G. Wand, M. Mccaul, Y. Kim, J. Frost (2004)
Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependenceBiological Psychiatry, 55
(2003)
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.Alcoholism, clinical and experimental research, 27 7
G. Wand, M. Mccaul, Xioaju Yang, J. Reynolds, Deidre Gotjen, Shing Lee, A. Ali (2002)
The Mu-Opioid Receptor Gene Polymorphism (A118G) Alters HPA Axis Activation Induced by Opioid Receptor BlockadeNeuropsychopharmacology, 26
R. Anton, S. O'Malley, D. Ciraulo, R. Cisler, D. Couper, D. Donovan, D. Gastfriend, J. Hosking, B. Johnson, J. Locastro, R. Longabaugh, B. Mason, M. Mattson, W. Miller, H. Pettinati, C. Randall, R. Swift, R. Weiss, L. Williams, A. Zweben (2006)
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.JAMA, 295 17
R. Kadden, C. Kathleen, D. Donovan, N. Cooney, P. Monti, D. Abrams, M. Litt, R. Hester (2003)
Cognitive behavioural coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence,
R. Anton, D. Moak, P. Latham, L. Waid, R. Malcolm, J. Dias, J. Roberts (2001)
Posttreatment Results of Combining Naltrexone with Cognitive-Behavior Therapy for the Treatment of AlcoholismJournal of Clinical Psychopharmacology, 21
C. Bouza, M. Angeles, A. Muñoz, J. Amate (2004)
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.Addiction, 99 7
H. Kranzler, J. Kirk (2001)
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.Alcoholism, clinical and experimental research, 25 9
D. Goldman, G. Oroszi, S. O'Malley, R. Anton (2005)
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.Journal of studies on alcohol. Supplement, 15
C Bouza, M Angeles, A Munoz, J Amate (2004)
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review [published correction appears in Addiction.2005;100(4):573]., 99
B. Johnson, S. O'Malley, D. Ciraulo, J. Roache, R. Chambers, O. Sarid‐Segal, D. Couper (2003)
Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprosate, Both Alone and Combined, in Alcohol-Dependent SubjectsJournal of Clinical Psychopharmacology, 23
B. Johnson, N. Rosenthal, Julie Capece, F. Wiegand, L. Mao, K. Beyers, Amy McKay, N. Ait-Daoud, R. Anton, D. Ciraulo, H. Kranzler, K. Mann, S. O'Malley, R. Swift (2007)
Topiramate for treating alcohol dependence: a randomized controlled trial.JAMA, 298 14
Esther Wildenberg, R. Wiers, J. Dessers, R. Janssen, E. Lambrichs, H. Smeets, G. Breukelen (2007)
A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.Alcoholism, clinical and experimental research, 31 1
K. Verebey, S. Mulé (1975)
Naltrexone pharmacology, pharmacokinetics, and metabolism: current status.The American journal of drug and alcohol abuse, 2 3-4
A. Bergen, J. Kokoszka, R. Peterson, J. Long, M. Virkkunen, M. Linnoila, D. Goldman (1997)
μ opioid receptor gene variants: lack of association with alcohol dependenceMolecular Psychiatry, 2
R. Anton, R. Swift (2003)
Current pharmacotherapies of alcoholism: a U.S. perspective.The American journal on addictions, 12 s1
J. Tonigan, W. Miller, J. Brown (1997)
The reliability of Form 90: an instrument for assessing alcohol treatment outcome.Journal of studies on alcohol, 58 4
H. Skinner, B. Allen (1982)
Alcohol dependence syndrome: measurement and validation.Journal of abnormal psychology, 91 3
M. Srisurapanont, N. Jarusuraisin (2005)
Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.The international journal of neuropsychopharmacology, 8 2
A. Arias, R. Feinn, H. Kranzler (2006)
Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis.Drug and alcohol dependence, 83 3
J. Lötsch, B. Stuck, T. Hummel (2006)
The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation.Behavioral neuroscience, 120 6
Cherie Bond, K. Laforge, M. Tian, Dorothy Melia, Shengwen Zhang, L. Borg, Jianhua Gong, J. Schluger, J. Strong, S. Leal, J. Tischfield, M. Kreek, Lei Yu (1998)
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.Proceedings of the National Academy of Sciences of the United States of America, 95 16
(1985)
Nalbuphine. Drug Alcohol Depend
Diagnostic and Statistical Manual of Mental Disorders.
ORIGINAL ARTICLE An Evaluation of µ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study Raymond F. Anton, MD; Gabor Oroszi, MD, PhD; Stephanie O’Malley, PhD; David Couper, PhD; Robert Swift, MD, PhD; Helen Pettinati, PhD; David Goldman, MD Context: Naltrexone hydrochloride treatment for alco- Main Outcome Measures: Time trends in percent- hol dependence works for some individuals but not for age of days abstinent, percentage of heavy drinking days, and rates of good clinical outcome. everyone. Asn40Asp, a functional polymorphism of the µ-opioid receptor gene (OPRM1), might predict naltrex- Results: Alcoholic subjects with an Asp40 allele receiv- one response. ing MM alone (no CBI) had an increased percentage of days abstinent (P=.07) and a decreased percentage of Objective: To evaluate whether individuals with alco- heavy drinking days (P=.04) if treated with naltrexone holism who are heterozygous (Asp40/Asn40) or homo- vs placebo, while those with the Asn40/Asn40 genotype zygous (Asp40/Asp40) for the OPRM1 Asp40 allele re- showed no medication differences. If treated with MM spond better to naltrexone. alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared
JAMA Psychiatry – American Medical Association
Published: Feb 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.